1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Agentix Corp.
  6. News
  7. Summary
    AGTX   US00848A1034

AGENTIX CORP.

(AGTX)
Delayed OTC Markets  -  05/27 01:13:38 pm EDT
0.1651 USD    0.00%
04/13AGENTIX CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)
AQ
04/13Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2022
CI
02/17HAPPENING TODAY : Agentix Corp. Presenting At The Emerging Growth Conference At 10:30am EST; Highlighting Clinical-Stage Developments and 2022 Initiatives
AQ
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

AGENTIX CORP. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Changes in Control or Registrant, Financial Statements and Exhibits (form 8-K)

05/29/2020 | 05:28pm EDT

Item 1.01 Entry into a Material Definitive Agreement.

On May 28, 2020, Agentix Corp., a Nevada corporation (the "Company"), entered into a Share Exchange Agreement (the "Share Exchange Agreement"), by and among the Company, and GSL Healthcare, Inc., a Nevada corporation ("GSL Healthcare"), and the holders of common stock of GSL Healthcare, which consisted of two stockholders.

Under the terms and conditions of the Share Exchange Agreement, the Company offered and sold 27,932,271 shares of common stock of the Company in consideration for all of the issued and outstanding shares of common stock of GSL Healthcare. The effect of the issuance is that former two GSL Healthcare shareholders now hold approximately 88.0% of the issued shares of common stock of the Company, and HSL Healthcare is now a wholly-owned subsidiary of the Company. GSL Healthcare has a general plan to be a health and wellness business. Until such time as the Company can formulate GSL Healthcare's general business plan, the Company is not changing its current business.

Item 2.01 Completion of Acquisition or Disposition of Assets

The information disclosed in Item 1.01 (Entry of Material Definitive Agreement) of this Form 8-K is hereby incorporated by reference into this Item 2.01.

Item 3.02 Unregistered Sales of Equity Securities.

The information disclosed in Item 1.01 (Entry of Material Definitive Agreement) of this Form 8-K is hereby incorporated by reference into this Item 2.01. We made the offer and sale of the 27,932,271 shares of common stock of the Company pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, in a non-public offering to two sophisticated persons who had access to registration-type of information about the Company.

Item 5.01 Changes in Control of Registrant.

Information disclosed in Item 1.01 (Entry of Material Definitive Agreement) of this Current Report on Form 8-K is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits:



Exhibit   Description

  2.1       Share Exchange Agreement, dated May 28, 2020, by and among the Agentix
          Corp., GSL Healthcare, Inc., a Nevada corporation, and the holders of
          common stock of GSL Healthcare, Inc.





2

© Edgar Online, source Glimpses

All news about AGENTIX CORP.
04/13AGENTIX CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
04/13Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended Febr..
CI
02/17HAPPENING TODAY : Agentix Corp. Presenting At The Emerging Growth Conference At 10:30am ES..
AQ
02/14AGENTIX CORP. TO PRESENT AT THE EMER : 30am EST; Highlighting Clinical-Stage Developments ..
AQ
01/13AGENTIX CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
01/13Agentix Corp. Reports Earnings Results for the First Quarter Ended November 30, 2021
CI
01/04AGENTIX Discusses 2022 Clinical Development Efforts and Potential Uplisting with The St..
NE
2021AGENTIX CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2021AGENTIX : Management's Discussion and Analysis Of Financial Condition and Results of Opera..
AQ
2021AGENTIX CORP. STOCK SURGES 27% ON NH : Agtx)
AQ
More news
Financials (USD)
Sales 2021 0,00  - -
Net income 2021 -1,34 M - -
Net cash 2021 0,00 M - -
P/E ratio 2021 -18,1x
Yield 2021 -
Capitalization 6,43 M 6,43 M -
EV / Sales 2020 -
EV / Sales 2021 19 685 850 806x
Nbr of Employees -
Free-Float 72,8%
Chart AGENTIX CORP.
Duration : Period :
Agentix Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Rudy A. Mazzocchi Chairman, President, CEO, CFO & CAO
Martin Schroeder Chief Scientific Officer
Rehan Huda Director
Salman Hoda Secretary, Treasurer & Senior VP-Portfolio
David Fiene Controller
Sector and Competitors
1st jan.Capi. (M$)
AGENTIX CORP.-66.98%6
CSL LIMITED-7.46%92 708
SAMSUNG BIOLOGICS CO.,LTD.-7.64%47 463
BIOGEN INC.-14.05%30 198
WUXI BIOLOGICS (CAYMAN) INC.-41.33%29 183
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-32.02%20 229